Under Turkish law, only entities registered in Türkiye are eligible to obtain a marketing authorization (“MA”) for medicinal products for human use. This requirement compels global pharmaceutical companies intending to engage in business in Türkiye to establish local presence either through forming a subsidiary or teaming up with a local partner such as a distributor. In case of a partnership (e.g., established through a distributorship relationship), transfer of MA will be one of the main topics to be discussed if and when such partnership comes to an end. This article provides an overview of the regulatory framework governing the transfer of MAs in Türkiye, with a particular focus on transfers where there may potentially be a disagreement between the transferor and the transferee.
According to the Regulation on the Licensing of Medicinal Products for Human Use (“Regulation”) and the Guidelines on Conditions Requiring Re-authorisation for Licensed Medicinal Products for Human Use, in order to transfer an MA, certain documents must be submitted to the Turkish Medicine and Medical Device Agency (“TMMDA”), and the relevant procedures must be completed. Transfer process has two main aspects: (i) submission of the transfer application to the TMMDA and (ii) cooperation of the transferor.
In the application for the transfer, the transferee must submit to the TMMDA: (i) a court decision stating that the transfer of MA has been fulfilled, (ii) an execution office decision stating that the license has been sold through forced execution proceedings, or (iii) a transfer agreement executed between the transferee and the transferor before a notary public.
Upon submission of the required documentation and payment of the application fees, the review process will commence where the TMMDA shall look into the application to confirm that all regulatory requirements are met, with a particular focus on whether the transferee is well equipped to manage the respective medicinal product in a responsible manner. The TMMDA shall make an assessment on the application within thirty days of the application date, and can request further information or documents, which would re-start the review period. Once the review process is completed, approval will be granted and the MA registry will be updated to reflect the change in the ownership, and the new holder will assume all rights and responsibilities associated with the authorisation.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
11 February 2026
New Merger Control Regulation From The Turkish Competition Board: Increased Turnover Thresholds And Special Regulation For Technology Undertakings
With the Communiqué Amending the Communiqué on Mergers and Acquisitions Requiring the Approval of the Competition Board (Communiqué No:…
6 February 2026
Legal Developments Regarding the Cultivation of Cannabis and Cannabis Products
The Regulation on Cannabis Cultivation and Control (“Regulation on Cannabis Cultivation”) and the Regulation on Products Derived from…
30 January 2026
Recent developments in Turkish data protection law
The end of 2025 and the beginning of 2026 have seen notable developments in Turkish data protection law, particularly regarding personal…
27 January 2026
Turkish Competition Authority Publishes Sector Inquiry Report On Handheld Terminals
The Sector Inquiry Report on Practices Concerning Handheld Terminals and Similar Devices (the “Report”), dated December 2025, was published…
21 January 2026
Key Legislative Developments in Renewable Energy and Electricity in 2025
2025 marked a period of comprehensive regulatory developments in the electricity market and renewable energy market. This legal alert…
20 January 2026
Thresholds for Initial Public Offerings Increased
As per the decision of the Capital Markets Board (the “CMB”) numbered 68/2461 and dated 30 December 2025, published in its bulletin dated…